UBS AM
ADPT icon

UBS AM’s Adaptive Biotechnologies ADPT Stock Holding History

UBS AM’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.77M Sell
222,280
-244
-0.1% -$3.74K ﹤0.01% 1631
2026
Q1 		$3.09M Buy
222,524
+19,799
+10% +$315K ﹤0.01% 1825
2025
Q4 		$3.29M Buy
202,725
+58,090
+40% +$948K ﹤0.01% 1667
2025
Q3 		$2.16M Sell
144,635
-122,258
-46% -$1.49M ﹤0.01% 1713
2025
Q2 		$3.11M Buy
266,893
+81,657
+44% +$742K ﹤0.01% 1942
2025
Q1 		$1.38M Buy
185,236
+66,643
+56% +$512K ﹤0.01% 2173
2024
Q4 		$711K Buy
+118,593
New +$654K ﹤0.01% 2471
2024
Q2 		– Sell
-203,941
Closed -$655K – 2796
2024
Q1 		$655K Buy
203,941
+32,649
+19% +$126K ﹤0.01% 2200
2023
Q4 		$839K Hold
171,292
– – ﹤0.01% 2120
2023
Q3 		$934K Buy
171,292
+48,375
+39% +$320K ﹤0.01% 1990
2023
Q2 		$1.09M Hold
122,917
– – ﹤0.01% 1965
2023
Q1 		$1.09M Buy
122,917
+10,731
+10% +$94.6K ﹤0.01% 1965
2022
Q4 		$857K Buy
112,186
+2,457
+2% +$19.1K ﹤0.01% 1919
2022
Q3 		$781K Buy
109,729
+3,329
+3% +$31.4K ﹤0.01% 2113
2022
Q2 		$861K Sell
106,400
-65,243
-38% -$574K ﹤0.01% 2048
2022
Q1 		$2.38M Buy
171,643
+16,285
+10% +$256K ﹤0.01% 1711
2021
Q4 		$4.36M Buy
155,358
+4,558
+3% +$140K ﹤0.01% 1483
2021
Q3 		$5.13M Buy
150,800
+2,394
+2% +$86.6K ﹤0.01% 1341
2021
Q2 		$6.06M Sell
148,406
-130,715
-47% -$5.08M ﹤0.01% 1288
2021
Q1 		$11.2M Buy
279,121
+1,364
+0.5% +$73.8K 0.01% 1047
2020
Q4 		$16.4M Buy
277,757
+32,266
+13% +$1.66M 0.01% 897
2020
Q3 		$11.9M Buy
245,491
+10,779
+5% +$453K 0.01% 900
2020
Q2 		$11.4M Buy
234,712
+170,766
+267% +$6.23M 0.01% 872
2020
Q1 		$1.78M Buy
63,946
+12,923
+25% +$360K ﹤0.01% 1459
2019
Q4 		$1.53M Sell
51,023
-280
-0.5% -$8.04K ﹤0.01% 1719
2019
Q3 		$1.59M Buy
51,303
+1,303
+3% +$53.2K ﹤0.01% 1722
2019
Q2 		$2.42M Buy
+50,000
New +$2.21M ﹤0.01% 1489

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS AM's ADPT Position: Q2 2026 in Review

UBS AM reduced its Adaptive Biotechnologies (ADPT) stake by 0.11% in Q2 2026, selling an estimated $3.74K and leaving 222,280 shares worth $4.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

UBS AM first reported a position in ADPT in Q2 2019 and has held it in 27 quarters since. The position peaked at $16.4M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • UBS AM held 222,280 shares of Adaptive Biotechnologies worth $4.77M as of Q2 2026.
  • UBS AM sold 244 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.74K.
  • Adaptive Biotechnologies made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1631 holding.
  • UBS AM first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 27 quarters since.
  • UBS AM's Adaptive Biotechnologies position peaked at $16.4M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.